Proteinuria Clinical Trials

A listing of Proteinuria medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 29 clinical trials
Featured trial
Non-diabetic Chronic Kidney Disease

We are currently recruiting participants for a clinical research study to evaluate new dosages of an FDA approved once daily medication to help improve kidney function in non-diabetic patients with Chronic Kidney Disease.

diabetes
  • 14 views
  • 26 Jan, 2023
  • 1 location
Safety and Pharmacokinetic Study of Subcutaneous ALXN1720 in Participants With Proteinuria

The primary objective of this study is to assess the impact of proteinuria on the pharmacokinetic (PK) of a single dose of ALXN1720 in participants with proteinuria.

hypertensive nephrosclerosis
diabetic nephropathy
glomerulosclerosis
nephropathy
  • 0 views
  • 04 Oct, 2022
Obinutuzumab in Primary FSGS

The purpose of this study is to evaluate the safety and efficacy of Obinutuzumab in inducing complete or partial remission of proteinuria.

  • 2 views
  • 07 Oct, 2022
  • 1 location
A 6-month Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety and PK/PD of an age-and Body Weight-adjusted Oral Finerenone Regimen, in Addition to an ACEI or ARB, for the Treatment of Children, 6 Months to <18 Years of Age, With Chronic Kidney Disease and Proteinuria (FIONA)

Researchers are looking for a better way to treat children who have chronic kidney disease (CKD), which is long-term kidney disease, and proteinuria, a condition in which a person´s kidneys leak

ace inhibitor
aldosterone
chronic kidney disease
hypertension
renin
  • 0 views
  • 16 Oct, 2022
  • 27 locations
A Phase 2, Open-Label, Single-Arm, Cohort Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Sparsentan Treatment in Pediatric Subjects With Selected Proteinuric Glomerular Diseases (EPPIK)

To evaluate the safety, efficacy and tolerability of sparsentan oral suspension and assess changes in proteinuria after once-daily dosing over the 108-week treatment period.

total protein
mammogram
kidney biopsy
glomerular filtration rate
corticosteroids
  • 1 views
  • 11 Oct, 2022
  • 26 locations
A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase III Study to Evaluate the Efficacy and Safety of LNP023 in Primary IgA Nephropathy Patients (APPLAUSE-IgAN)

maximally tolerated ACEi or ARB on reduction of proteinuria and slowing renal disease progression in primary IgA Nephropathy patients.

treatment regimen
hbeag
mammogram
nephropathy
fibrosis
  • 45 views
  • 24 Oct, 2022
  • 170 locations
A Randomized, Open-label, Two Arm, Parallel Group, Proof-of-concept Clinical Trial to Investigate the Efficacy and Safety of LNP023 Compared With Rituximab in the Treatment of Subjects With Idiopathic Membranous Nephropathy

membranous nephropathy (MN) who are at high risk of disease progression defined on the basis of antibody anti-PLA2R titre and proteinuria.

kidney biopsy
diuretics
rituximab
proteinuria
lnp023
  • 30 views
  • 20 Oct, 2022
  • 32 locations
A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Iptacopan (LNP023) in Complement 3 Glomerulopathy. (APPEAR-C3G)

The study is designed as a multicenter, randomized, double-blind, parallel group, placebo-controlled study to evaluate the efficacy and safety of iptacopan (LNP023) in complement 3 glomerulopathy.

  • 37 views
  • 24 Oct, 2022
  • 53 locations
Atrasentan in Patients With IgA Nephropathy (ALIGN)

The ALIGN Study is a phase 3, double-blind, placebo-controlled study to compare the efficacy and safety of atrasentan to placebo in patients with IgA nephropathy (IgAN) at risk of progressive loss of renal function.

renal function
nephropathy
  • 47 views
  • 04 Oct, 2022
  • 119 locations
Atrasentan in Patients With Proteinuric Glomerular Diseases (AFFINITY)

The AFFINITY Study is a phase 2, open-label, basket study to evaluate the efficacy and safety of atrasentan in patients with proteinuric glomerular disease who are at risk of progressive loss of renal function.

sglt2
type 2 diabetes mellitus
renal function
kidney function tests
atrasentan
  • 31 views
  • 04 Oct, 2022
  • 36 locations